Used primarily in the development of targeted drug delivery systems, this compound serves as a linker in bioconjugation strategies. Its structure allows for the attachment of therapeutic agents to targeting molecules, enhancing the precision of drug delivery to specific cells or tissues. This is particularly useful in cancer therapy, where minimizing damage to healthy cells is crucial. Additionally, it is employed in the creation of antibody-drug conjugates (ADCs), which combine the specificity of antibodies with the potency of cytotoxic drugs to effectively treat various malignancies. The PEG (polyethylene glycol) segment improves solubility and stability, reducing the likelihood of immune system recognition and clearance, thereby increasing the therapeutic agent's circulation time in the body.